StockMarketWire.com - Hutchison China MediTech said Friday its lung cancer treatment did not meet its primary objective after failing to demonstrate a 'statistically significant' increase in overall survival.

The results emerged from its phase 3 Faluca trial, which examined the efficacy of the lung cancer drug Fruquintinib in treating patients with advanced non-small cell lung cancer patients in China who had failed two lines of systemic chemotherapy.

Fruquintinib had demonstrated a 'statistically significant' improvement in all secondary endpoints including progression-free survival, objective response rate, disease control rate and duration of response as compared to the placebo, the company said.

'While the study demonstrates a significant reduction in disease progression in this challenging lung cancer patient population, we are disappointed that this benefit did not translate into an increase in overall survival,' said Simon To, Chairman of Chi-Med.

'We remain confident that the high selectivity and lower off-target toxicities of fruquintinib are major points of differentiation. The recent first approval of fruquintinib monotherapy for advanced colorectal cancer, the imminent launch in China, and the commencement of several combination collaborations with immunotherapies both in China and in the U.S., reinforces our belief in fruquintinib.'










At 8:52am: [LON:HCM] Hutchison China Meditech Ltd share price was -1080p at 4520p



Story provided by StockMarketWire.com